SWAV
- ShockWave Medical, Inc.
()
Overview
Company Summary
ShockWave Medical, Inc. (SWAV) is a medical technology company that specializes in the development and commercialization of intravascular lithotripsy (IVL) technology. IVL is a cutting-edge, non-invasive technology used in the treatment of calcified cardiovascular disease.
The company's proprietary IVL technology utilizes sonic pressure waves to safely and effectively treat calcium deposits in blood vessels, including those that cause blockages in the arteries leading to the heart and peripheral arteries in the legs. These calcium deposits, known as calcified plaques, can restrict blood flow, leading to serious conditions such as peripheral artery disease (PAD) and coronary artery disease (CAD).
ShockWave Medical's IVL technology is designed to deliver sonic pressure waves through a minimally invasive catheter, which helps to gently disrupt and fracture the calcified plaques. This process, called lithotripsy, enables the restoration of blood flow by allowing the vessel to expand and return to its normal state. The procedure provides a more effective alternative to traditional treatment options, such as atherectomy (removal of plaque) or balloon angioplasty (opening up blocked arteries with a balloon).
The company's flagship product, the Shockwave Coronary Intravascular Lithotripsy (C2L) System, is specifically designed for use in coronary arteries treating patients with CAD. Additionally, ShockWave Medical offers the Shockwave Peripheral Intravascular Lithotripsy (P2L) System, which is used for the treatment of PAD.
SWAV aims to provide interventional cardiologists and peripheral vascular specialists with a safe and precise tool to address calcified plaques and improve patient outcomes. By enabling effective vessel preparation, ShockWave Medical's innovative technology has the potential to enhance the success of subsequent procedures like stent implantation and increase long-term treatment durability.
In summary, ShockWave Medical, Inc. focuses on developing and commercializing innovative intravascular lithotripsy technology to address the challenging issue of calcified plaque in cardiovascular disease. Through their advancements, the company aims to provide effective, minimally invasive treatment options for patients suffering from a range of conditions caused by calcified deposits in blood vessels.